NS1 is the only nonstructural protein that enters the lumen of the endoplasmic reticulum 1
Using TopCount microplate scintillation and a luminescence counter (Packard), the RLuc activity 138 of each mutant NS1-expressing plasmid was normalized to the internal control of FLuc activity, 139 and was presented as the relative luciferase expression. 140
Recovery of recombinant virus 142
The construction of DNA-launched version of JEV RP-9 (rRP-9) infectious cDNA clone was 143 as described previously (24). To recover the infectious virus, 1 μg samples of plasmids of 144 340SP70, 343SP70, 352SP70 or 352VP2-28 were transfected into BHK-21 cells with 145
Lipofectamine 2000 (Invitrogen), and when cytopathic effects (CPE) had occurred in these cells, 146 the culture supernatants were collected and transferred to C6/36 cells for further amplification. 147
Virus titers (in PFU/ml) were determined by plaque-forming assays on BHK-21 cells. To assess 148 the genetic stability of the inserted sequences in the recombinant JEV, we amplified each 149 recombinant JEV in Vero cells for 6 serial passages. After infecting cells with viruses of different 150 passages (P2, P4, and P6), total RNA were extracted from infected cells using a Total RNA 151 purification kit (GeneMark), and the resulting RNA samples were reverse transcribed with 152 SuperScript III (Invitrogen) using a specific primer (5'-TTAGAAGCGCTAAGACTGG-3'). Then, 153 the RT product was used as a template to perform a PCR reaction using primers 154 (5'-GAGAGCACTGACGAGTG TGATGGAGCG-3' and 5'-TTAGAAGCGCTAAGACTGG-3') 155 flanking the inserted sequences. The PCR products were analyzed using restriction enzyme HincII 156 digestion and further verified by DNA sequencing.
BHK-21 cells were infected with each recombinant JEV at a multiplicity of infection (MOI) of 5. 160
After 1 h of adsorption at 37°C, unbound viruses were removed from cells by three washes with 161 PBS. The infected cells were then grown in RPMI 1640 medium supplemented with 2% FBS at 162 37°C. At various times postinfection, the supernatants alone or cell-associated viruses and 163 supernatants (total viruses) of infected cells were collected. Next, the virus titers were determined 164 by plaque assay on BHK-21 cells as previously described (22) . 165
166

Western blot analysis 167
To investigate whether insertion of the EV71 epitope into the C-terminus of JEV NS1 168 affected the NS1 protein expression and secretion, BHK-21 cells were mock-infected or infected 169 with rRP-9, 340SP70, 343SP70, 352SP70, 352VP2-28, or 352-long-bc at MOI 5. After 48h of 170 infection, cell lysates and culture medium were collected and the medium concentrated using a 171 PALL Nanosep device (MWCO=10K) according to the manufacturer's instructions. Cell lysates 172 and concentrated medium were treated either by boiling plus 2-mercaptoethanol reduction or by 173 not boiling without 2-mercaptoethanol reduction. Then, protein samples were separated using 10% 174 SDS-PAGE and transferred to nitrocellulose membranes (Hybond-C Extra; Amersham 175 Biosciences). After blocking with 5% skim milk for 1h, the membranes were incubated with 176 mouse monoclonal antibody J2-54 for JEV NS1 (1:1000), polyclonal antibody PAB7630-B01P for 177 
Recovery of viable JEV recombinants with fusion EV71 epitope in the C-terminus of NS1 285
Using the infectious cDNA clone JEV rRP-9 (24) as the backbone, we next converted the 286 replicable NS1-SP70 replicons ( Fig. 1 ) into the corresponding infectious viruses ( Fig. 2A) . 287
Similarly, we also constructed a recombinant JEV named 352VP2-28, housing the second EV71 288 neutralizing epitope VP2-28 (21) inserted in the C-terminus of NS1, which was derived from its 289 virus coat subunit VP2 (residues 131-155) of VIGTVAGGTGTEDSHPPYKQTQPGD ( Fig. 2A) . 290
Except for 340SP70, all other recombinant viruses were successfully recovered from the 291 transfected BHK-21 cells (Fig. 2B ). Among them, the plaque size of the NS1-intragenic inserted 292 virus of 343SP70 was smaller than those of the uninterrupted NS1 fusion counterparts 352SP70 293 and 352VP2-28, as well as parental rRP-9 (Fig. 2B) . The stability of the inserted sequences in the 294 recombinant viruses was examined by RT-PCR restriction profile analysis and direct sequencing, 295
and representative results from the indicated viruses were shown in Fig. 2C , from which the 296 inserted segments were stably retained during 6 passages in infected Vero cells. Full-genome 297 sequencing also confirmed that these inserted sequences remained unchanged, and no 298 compensatory mutations were found in other coding regions. By one-step growth curve analysis in 299 on December 28, 2017 by guest http://jvi.asm.org/ Downloaded from BHK-21 cells, we observed that the virus growth kinetics of 352SP70 and 352VP2-28 were 300 comparable to that of parental virus rRP-9 for both the total amount and the viruses released in the 301 supernatants, whereas 343SP70 exhibited a slower growth pattern than rRP-9 (Fig. 2D) . Together, 302 these results clearly illustrated that the C-terminus of NS1 is flexible for JEV to accommodate 303 insertion of foreign epitopes without significantly affecting the virus viability. 304 305
Dimeric and secreted forms of NS1-EV71-epitope or NS1-long-bc fusion proteins are 306
properly expressed from recombinant JEV-infected cells 307 Flavivirus NS1 is highly immunogenic to the host, partly due to its ability to secrete from 308 infected cells and to form multimers (3). We examined the effects of EV71 epitope insertion on 309 dimerization and secretion abilities of NS1-SP70 or NS1-VP2-28 fusion proteins during infection. 310
We first infected BHK-21 cells with the indicated recombinant JEV (Fig. 3) , and the viral antigens 311 in cell lysates or culture medium were collected for western blotting using antibodies specifically 312 recognizing JEV-NS1, EV71-VP1 or EV71-VP2. These protein samples were prepared through 313 either being boiled to detect monomeric or leaving unboiled to detect dimeric NS1-EV71-epitope 314 fusion proteins. As compared with the parental virus rRP-9 shown in 352-long-bc. As shown in Fig. 3E and 3F, we found these NS1-or NS1'-fusion proteins could be 328 expressed normally in monomeric (panels E and F, lanes 1 and 2) and dimeric forms (panels E and 329 (Fig. 4) . These 354 observations indicated that such inserted epitopes in dimeric NS1 proteins appeared to be all 355 exteriorly exposed. 356
Furthermore, in the modeled hexameric structures of NS1-EV71-epitope proteins, we 357 observed that at least four out of six inserted epitopes from 352SP70 (Fig. 4G, spots in red) and 358 352VP2-28 (Fig. 4H , spots in red) could expose outside the hexamers; similarly, all six units of 359 heterologous insertion could also expose superficially from its NS1 hexamer of 343SP70 (Fig. 4F,  360 spots in red). These results thus suggested that foreign epitopes can be readily accessible to elicit a 361 humoral immune response when fused with flavivirus NS1 at its C-terminal tip region of the core 362 β-ladder domain, which appears to be not only flexible in terms of housing extra insertions, but 363 also ensures that the inserted epitopes are properly exposed outwards from NS1 multimers. 364 365 NS1-fusion recombinant JEV, despite exhibiting attenuated virulence, could confer sufficient 366 protection to mice against lethal JEV challenge 367 JEV rRP-9 is a wild-type strain with a high neurovirulence for challenged mice, whereas 368 vaccine strain RP-2ms is much less neurovirulent than rRP-9 (25-26). To examine the effect of 369 epitope insertion into NS1 on the virulence of rRP-9 towards infected hosts, we i.p. 5 PFU of rRP-9 could readily kill all mice within 11 days, while that of RP-2ms was 373 completely harmless to mice (Fig. 5A) . On the other hand, NS1-fusion recombinant JEV exhibited 374 varied extents of attenuation to the challenged mice as compared with the parental rRP-9 (Fig. 5A) . 375
All surviving animals from Fig. 5A completely resisted subsequent lethal JEV challenge (data not 376 shown), indicating that such attenuated recombinants could confer sufficient protection against 377 fatal homologous challenge. Moreover, with the exception of 343SP70, the replication capability 378 in the brain appeared to be comparable among 352SP70, 352VP2-28 and parental rRP-9 when we 379 directly injected 10 2 PFU of the viruses into mouse brains (Fig. 5B) . Following i.p. inoculation 380 with 10 5 PFU of the viruses, we observed that the tissue tropism profiles in the mice were similar 381 to each other between the NS1-fusion recombinants and parental rRP-9, which were mostly 382 detected in the spleen, liver and spinal cord (Fig. 5C) . 383
We next examined whether mother dams immunized with NS1-fusion recombinants could 384 confer protective immunity to their 1-day-old neonatal mice against a later lethal JEV rRP-9 385 challenge according to the prime-boost protocol shown in Fig. 5D . As Fig. 5E Through conducting the immunoblot assay of sera derived from the given immunized mice, 394
we observed that recombinants 343SP70 and 352SP70 could induce antibody responses specific to 395 EV71-VP1 protein (Fig. 6A) . Using a mouse-adapted EV71/MP4 strain (genotype C2) that readily 396 causes death in newborn mice (27), we found that 343SP70-immunized sera had neutralizing titers 397 ranging from 8 to 16, whereas 352SP70-and 352VP2-28-immunized sera exhibited higher 398 neutralizing titers ranging from 16 to 32, significantly higher than the control PBS or 399 rRP-9-immunized sera (Fig. 6B) . 400
We therefore examined whether NS1-EV71-epitope fusion recombinant JEV could trigger a 401 protective immunity against lethal challenge by heterologous EV71. As the prime-boost protocol 402 shown in Fig. 6C , we immunized female ICR mice with the indicated NS1-fusion recombinants 403 and then lethally challenged their neonatal mice with EV71/MP4. We first determined that the 404 50% lethal dose (LD 50 ) of EV71/MP4 was 40 PFU/mouse, and decided accordingly to inject the 405 newborns i.p. with 3 LD 50 of EV71/MP4, then monitored mouse lethality for 21 days. We found 406 that, as the control, neonatal mice from the PBS-or rRP-9-immunized dams gradually exhibited 407 on December 28, 2017 by guest http://jvi.asm.org/ Downloaded from mobility reduction, limb weakness, and paralysis, and all died within 10 days; however, newborns 408 from dams immunized with 343SP70, 352SP70 or 352VP2-28 exhibited survival rates of 22% 409 (6/27), 55% (16/29) and 60% (18/30), respectively, with only transient and minor neurological 410 symptoms (Fig. 6D) . Together, the results shown in 352 provided that we supplied the final 12 aa of NS1, which were in-frame fused with the foreign 438 epitopes ( Fig. 1 and 2) . Importantly, we found that all recombinant JEV could secrete soluble NS1 439 and NS1' in their correct multimeric forms, as per their parental rRP-9, from infected cells (Fig. 3) . 440
Because the secreted hexamer of flavivirus NS1 is known to be highly immunogenic (3), we in 441 homology-modeling algorithm analysis, and observed three distinguishable domains from JEV 459 NS1 protein (Fig. 4) , including a small β-roll dimerization domain, a protruding wing domain and 460 a predominant core β-ladder domain. Our EV71-neutralizing epitopes were successfully inserted 461 into the tip region (278-352 aa), and were in fact located at each end of the core β-ladder domain 462 (Fig. 4, panels B, C, D, F, G, and H) . As at least 108 linear epitopes have been previously 463 identified and mapped onto the NS1 hexamer structure (5), this C-terminal tip region of the core 464 β-ladder domain appears to be the one of the most accessible parts recognized by many 465 NS1-specific monoclonal antibodies (5). Noticeably, we observed that most of the inserted EV71 466 epitopes in the tip of the β-ladder domain appeared to be properly exposed outwards from the 467 modeled recombinant JEV NS1 structures in dimers and hexamers (Fig. 4, ribbons and spots in  468 on December 28, 2017 by guest http://jvi.asm.org/ Downloaded from red). Moreover, immunization with such NS1-fusion recombinant JEV could elicit EV71-specific 469 neutralizing antibodies (Fig. 6B ) from mother dams, which, through crossing the placenta, could 470 subsequently confer on their newborns a dual protective immunity against lethal challenges by 471 JEV (Fig. 5E) and EV71 (Fig. 6D) . These results therefore suggested that foreign epitopes, when 472 while the insertion capacity of the flavivirus E protein is 16 aa in its fg loop region (16), we found 484 in this study that JEV NS1 could otherwise accommodate inserted epitopes ranging from 22 to 70 485 aa in length, which was in fact longer than the 56-aa insertion reported for YFV NS1 at residue 486 on December 28, 2017 by guest http://jvi.asm.org/ Downloaded from 236 (18). We achieved this greater insertion capacity by choosing the insertion site in JEV NS1 to 487 be the very last residue, 352, where the inserted epitopes had extra 12aa derived from the 488 C-terminal end of NS1 in order to properly separate NS1 from NS2A during infection (Fig. 2) . 489
The resulting viruses 352SP70 and 352VP2-28 appeared to confer more efficient protection 490 against lethal EV71 challenge (Fig. 6D) . Our results thus clearly illustrated that JEV NS1 appears 491 to be satisfactorily manipulatable in the context of the whole virus level, providing that the inserts 492 of interest are integrated in its C-terminal end. However, such an insertion into JEV NS1 with 493 neutralizing epitopes should strictly limit only to the linear nature of the epitopes derived from 494 other viruses, rather than discontinuous/conformational epitopes or those recognizing interdomain 495 or quandary structures present only on virions. Moreover, it is unclear whether a single 496 neutralizing epitope is sufficient as a vaccine to provide protection in humans. It thus remains to 497 be further investigated about the potential application of JEV-NS1 fusion epitopes developed here 498 through a comparison study including use of such as VP1/2-subunit vaccines, formalin-inactivated 499 whole virus and virus-like particle vaccines. In conclusion, we successfully established in this 500 study a novel and versatile JEV expression platform through exploiting NS1 as a multimeric 501 carrier to properly represent heterologous epitopes during infection. Conceivably, we may 502 therefore be able to swiftly build up a series of recombinant JEV that can simultaneously elicit 503 dual/multiple protective immunities against different infections by a single immunization. 504 
